{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-001179","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-09-02T21:06:24+00:00","discovered_at":"2026-09-02T21:08:00.411381+00:00","generated_at":"2026-09-02T21:08:05.197814+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Anavex regains Nasdaq compliance after filing delinquent 10-Qs for Q2 and Q3 FY2026","bullets":["Nasdaq confirmed compliance with Listing Rule 5250(c)(1) on September 2, 2026.","Delinquency notice received May 20, 2026; compliance plan submitted July 20, 2026.","Filed 10-Qs for periods ended March 31 and June 30, 2026 on August 28, 2026.","Common stock continues trading on Nasdaq Global Select Market under ticker AVXL.","Company cites advancing all three core CNS indications as ongoing strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-001179","json":"https://secwatch.observer/filing/0001731122-26-001179.json","markdown":"https://secwatch.observer/filing/0001731122-26-001179.md","text":"https://secwatch.observer/filing/0001731122-26-001179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001179/0001731122-26-001179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001179/e7909_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-02T21:08:05.197814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}